Clinical trial
Interleukin-12 in Treating Patients With Multiple Myeloma
NCT00003149 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00003149 |
|---|---|
| Title | Interleukin-12 in Treating Patients With Multiple Myeloma |
| Official title | Phase II of Interleukin-12 for Plateau Phase Multiple Myeloma |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Biological |
| Interventions | recombinant interleukin-12 |
| Enrollment | 40 |
| Start date | Dec 1, 1997 |
| Completion | Sep 1, 2006 |
| First posted | Mar 30, 2004 |
| Last update posted | Jun 21, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: